Cargando…
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
The purpose of our study was to investigate the efficacy and toxicity of paclitaxel in patients with relapsed or refractory epithelial ovarian cancer in the context of a large multicentre study performed in the UK and Eire. Patients with previously treated epithelial carcinoma of the ovary or fallop...
Autores principales: | Gore, M. E., Levy, V., Rustin, G., Perren, T., Calvert, A. H., Earl, H., Thompson, J. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034015/ https://www.ncbi.nlm.nih.gov/pubmed/7547214 |
Ejemplares similares
-
Phase II trial of trimelamol in refractory ovarian cancer.
por: Judson, I. R., et al.
Publicado: (1991) -
How Taxol/paclitaxel kills cancer cells
por: Weaver, Beth A.
Publicado: (2014) -
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours
por: McNeish, I A, et al.
Publicado: (2004) -
Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995) -
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
por: Liebmann, J. E., et al.
Publicado: (1993)